DOR BioPharma starts orBEC NPAP for ASEAN region

DOR BioPharma, a late-stage, US biopharmaceutical company developing products to treat the life-threatening side effects of cancer therapies and serious gastrointestinal diseases, as well as vaccines against certain bioterrorism agents, has entered into a collaboration with Pacific Healthcare Thailand, under which the latter will act as DOR's sponsor to administer a Named Patient Access Program (NPAP) for orBec (oral beclomethasone dipropionate) to patients suffering from acute gastrointestinal graft-versus-host disease in Thailand as well as other Association of Southeast Asian Nations member countries including Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines and Vietnam.

The NPAP is a compassionate-use drug supply program under which medical practitioners can legally supply investigational drugs to their eligible patients. Under this program, such medicines can be administered to patients who are suffering from serious illnesses until the drug is approved by the various regional regulatory authorities. Pacific and DOR will share revenues generated by sales of orBec through the NPAP, while the US firm will manufacture and supply orBec to Pacific, which will be responsible for all distribution costs in the assigned ASEAN territory.